Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Retinal Vein Occlusion Clinical Trial

— CAPTURE  

Official title:

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01875770
• Other study ID #: NA_00079952
• Status: Terminated
• Start date: January 2013
• Est. completion date: March 3, 2021

Study information

• Verified date: May 2021
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Description:

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 47
• Est. completion date: March 3, 2021
• Est. primary completion date: October 11, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• All patients who have been enrolled in the following three trials will be included in the study:

A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Retinal Vein Occlusion

Locations

Country	Name	City	State
United States	Wilmer Eye Institute	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline in BCVA at 5 and 10 years.	Mean change from baseline in BCVA at 5 and 10 years.	10 years
Secondary	Mean change from baseline in foveal thickness at 5 and 10 years	Mean change from baseline in foveal thickness at 5 and 10 years	10 years